Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS PROVIDED/(USED) BY OPERATING ACTIVITIES
Net income	$ 6,658	$ 1,116
Adjustments to reconcile net loss to net cash provided/(used) by operating activities:
Depreciation and amortization	1,081	1,604
Extinguishment of PPP loan		(2,045)
Loss on extinguishment of term debt	792
Gain on sale of Microlab	(16,490)
Amortization of debt issuance fees	55	217
Share-based compensation expense	950	302
Deferred rent	(22)	(22)
Deferred income taxes	3,169	(387)
Provision for doubtful accounts	(13)	72
Inventory reserves	35	115
Changes in assets and liabilities, net of divestiture:
Accounts receivable	(2,052)	(1,998)
Inventories	(960)	(993)
Prepaid expenses and other assets	(88)	459
`Accounts payable	506	728
Deferred revenue	(285)	(225)
Accrued expenses and other liabilities	(1,034)	1,592
Net cash provided/(used) by operating activities	(7,698)	535
CASH FLOWS PROVIDED/(USED) BY INVESTING ACTIVITIES
Capital expenditures	(582)	(417)
Deferred purchase price payment	(250)	(200)
Divestiture of Microlab, net	22,969
Net cash provided/(used) by investing activities	22,137	(617)
CASH FLOWS USED BY FINANCING ACTIVITIES
Revolver borrowings/(repayments), net		45
Term loan borrowings		345
Term loan repayments	(4,422)	(4,191)
Acquisition of treasury stock	(2,525)
Payment of contingent consideration	(1,097)	(460)
Proceeds from exercise of stock options	137	209
Shares withheld for employee taxes	(26)	(44)
ATM share sold		565
Net cash used by financing activities	(7,933)	(3,531)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(252)	(14)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	6,254	(3,627)
Cash and Cash Equivalents, at Beginning of Period	4,472	4,910
CASH AND CASH EQUIVALENTS, AT END OF PERIOD	10,726	1,283
SUPPLEMENTAL INFORMATION:
Cash paid during the period for interest	122	698
Cash paid during the period for income taxes	$ 957	$ 150